DON'T PANIC!
Common antibiotics carry small but serious risks of life-threatening drug reactions, but some are safer than others
image:
Common antibiotics carry serious risk
of life-threatening drug reactions,
but safer options exist
Credit: ICES
Toronto, ON, May 15, 2024 – Two classes of commonly prescribed oral antibiotics are associated with the greatest risk for severe drug rashes that can lead to emergency department visits, hospitalizations and even death, according to a new study.
Researchers from ICES, Sunnybrook Research Institute and the Department of Medicine at the University of Toronto’s Temerty Faculty of Medicine suggest that prescribers should consider using lower-risk antibiotics for their patients when clinically appropriate.
Serious cutaneous adverse drug reactions (cADRs), or severe drug rash, are a group of rare but potentially life-threatening delayed reactions involving the skin and, often, internal organs. Some of these reactions carry mortality rates from 20 to 40%. While many different classes of drugs can cause serious cADRs, antibiotics are among the most commonly reported triggers for these reactions.
“Clinicians have speculated that certain antibiotics carry greater risk for these severe reactions, but no study has ever confirmed these claims” says Erika Lee, an allergist and a trainee with ICES and Temerty Medicine’s Eliot Phillipson Clinician-Scientist Training Program. “Our objective was to explore the risk for cARDs in a population of older adults, who tend to receive disproportionately more antibiotic prescriptions than younger adults.”
Published in the journal JAMA, this case-control study used healthcare data from ICES of adults 66 years or older who received a prescription for at least one oral antibiotic between 2002 and 2022 in Ontario, Canada.
Over the study period, 21,758 adults had an ED visit or hospitalization for a serious cADR following oral antibiotics and were matched with 87,025 controls who did not have a reaction.
Risk highest for two classes of antibiotics
“The good news is that most patients who visited the hospital with these reactions were discharged without being admitted, so that should be reassuring to providers and patients,” says Lee. “However, of those who were admitted to hospital with the most severe reactions, twenty percent were treated in the ICU, and five percent of hospitalized patients died, which underscores the need for careful prescribing practices.”
The most commonly prescribed antibiotics were penicillins (29%), followed by cephalosporins (18%), fluoroquinolones (17%), macrolides (15%) nitrofurantoin (9%) and sulfonamides (6%). Less commonly prescribed antibiotics were grouped together and accounted for 7% of prescriptions.
Key findings include:
All antibiotics were associated with a higher risk of serious cADRs relative to macrolides, but sulfonamides (“sulfa drugs”) and cephalosporins were associated with the highest risk.
There were 2 cADR-related hospital visits for every 1000 antibiotic prescriptions dispensed
About 1 in 8 patients presenting to the ED with antibiotic-related cADRs was hospitalized, likely because their reactions were more severe or because of concerns about potential complications.
20% of hospitalized patients with the most severe forms of cADRs were treated in a critical care unit, and 5% of those patients died.
Greater awareness needed
“While rare, these severe drug reactions can be life-threatening. Patients should be aware of rash, fever, and other symptoms, which can start weeks after a prescription has been started and even after the course of antibiotics has stopped,” says David Juurlink, a staff internist and head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre, senior core scientist with ICES and professor of medicine with Temerty Medicine.
“It’s also one more reason why antibiotics should be prescribed only when they’re truly needed,” he adds.
The article, “Oral antibiotics and the risk of serious cutaneous adverse drug reactions,” was published in JAMA.
Founded in 1827, the University of Toronto is Canada's top university with a long history of challenging the impossible and transforming society through the ingenuity and resolve of its faculty, alumni and supporters. We are proud to be one of the world's top research-intensive universities, bringing together top mins from every conceivable background and discipline to collaborate on the world’s most pressing challenges.
Our community is a catalyst for discovery, innovation and progress, creating knowledge and solutions that make a tangible difference around the globe. And we prepare our students for success through an outstanding global education rooted in excellence, inclusion and close-knit learning communities.
The ideas, innovations and contributions of more than 679,00 graduates advance U of T’s impact on communities across the globe. Together, we continue to defy gravity by taking on what might seem unattainable today and generating the ideas and talent needed to build a more equitable, sustainable and prosperous future.
Sunnybrook Research Institute (SRI) is the research arm of Sunnybrook Health Sciences Centre, an internationally recognized academic health sciences centre fully affiliated with the University of Toronto. With well-established programs in basic and applied sciences which span across three scientific platforms and ten clinical programs, SRI is developing innovations in care for the more than 1.1 million patient visits the hospital provides annually. Recognized as a Centre of Excellence in focused ultrasound, SRI has one of the most comprehensive and successful focused ultrasound research programs in the world, with technical, scientific and clinical experts accelerating progress in the field. Learn more at Sunnybrook.ca/research.
ICES is an independent, not-for-profit research and analytics institute that uses population-based health information to produce knowledge on a broad range of healthcare issues. ICES leads cutting-edge studies and analyses evaluating healthcare policy, delivery, and population outcomes. Our knowledge is highly regarded in Canada and abroad and is widely used by government, hospitals, planners, and practitioners to make decisions about healthcare delivery and to develop policy. For the latest ICES news, follow us on X, formerly Twitter: @ICESOntario
FOR FURTHER INFORMATION PLEASE CONTACT:
Misty Pratt
Senior Communications Associate, ICES
Misty.Pratt@ices.on.ca
Nadia Norcia Radovini
Communications Advisor, Sunnybrook Health Sciences Centre
media@sunnybrook.ca 416.480.4040
Blake Eligh
Media Relations Specialist, Temerty Faculty of Medicine
blake.eligh@utoronto.ca 647-615-9763
U of T Media Relations
media.relations@utoronto.ca (416) 978-0100
Journal
JAMA
Method of Research
Observational study
Subject of Research
People
Article Title
Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions
Article Publication Date
8-Aug-2024
Oral antibiotics and risk of serious cutaneous adverse drug reactions
JAMA Network
About The Study: Commonly prescribed oral antibiotics are associated with an increased risk of serious cutaneous adverse drug reactions compared with macrolides, with sulfonamides and cephalosporins carrying the highest risk. Prescribers should preferentially use lower-risk antibiotics when clinically appropriate.
Corresponding Author: To contact the corresponding author, David N. Juurlink, M.D., Ph.D., email david.juurlink@ices.on.ca.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.11437)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.11437?guestAccessKey=b6941536-d19f-48d1-8cf7-c6f37bf9d5b0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=080824
Journal
JAMA
No comments:
Post a Comment